Takeda teams with enGene for gastrointestinal R&D

Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. Under the agreement, enGene will develop two treatments matching up to Takeda-selected targets through preclinical studies, and the major drugmaker will take the reins from there, promising its partner an upfront payment and milestones tied to R&D. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.